“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

Adults as young as 50 may now qualify for an respiratory synctial virus vaccine if they have certain health conditions.

Failure to recognize and resolve problems in an honest and evidence-based manner is the root cause of increasing vaccine ...

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...

The label expansion sought by GSK is a bid to compete with Pfizer and Moderna in the younger age groups of the RSV vaccine market. Pfizer’s Abrysvo and Moderna’s mRESVIA are both approved to prevent ...

GSK plc GSK announced that the FDA has accepted its regulatory filing seeking to expand the use of its RSV vaccine, Arexvy, in adults under 50 who are at a higher risk of the disease. A final decision ...

The Trump administration appears to be expanding RSV vaccinations to some adults starting at age 50, down from 60, following ...

Vaccines do much more than prevent specific diseases — their side benefits save children's lives around the world ...

If I have sounded like a broken record these past months, it is because these developments in American public health are as ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...